艾力斯(688578.SH):與ArriVent就伏美替尼海外權益簽署相關合作協議
格隆匯6月30日丨艾力斯(688578.SH)公佈,為拓展公司核心產品甲磺酸伏美替尼(“伏美替尼”)在海外市場的開發及商業化,公司擬與 ArriVent Biopharma Inc.,(“ArriVent”)簽署《全球技術轉讓和授權協議》和《普通股認購協議》(以下合稱“關聯交易協議”),就伏美替尼在海外市場的開發及商業化達成整體合作。
公司擬授權ArriVent使用公司伏美替尼相關專利和專有技術,在除中國大陸、台灣、香港和澳門外的地區獨家開發(包括研發、生產、進口、出口、使用、銷售等)伏美替尼的權利,公司將獲得4000萬美元的首付款,累計不超過7.65億美元的研發和銷售里程碑款項(達到約定的研發或銷售里程碑事件),銷售提成費,以及ArriVent一定比例的股份,ArriVent將成為公司的參股公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.